Clinical Trials Logo

Addiction clinical trials

View clinical trials related to Addiction.

Filter by:

NCT ID: NCT05976178 Recruiting - Chronic Pain Clinical Trials

Study of the Characteristics of Chronic Pain in Patients With Addiction

ADDICTALGO
Start date: December 10, 2022
Phase:
Study type: Observational

It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder. Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care. The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain. The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.

NCT ID: NCT05941195 Completed - Clinical trials for Substance Use Disorders

Investigation of the Effect of Cognitive Behavioral Approach-Based Psychoeducation

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This study, which was planned to examine the effects of cognitive behavioral approach-based psychoeducation on addiction profiles, self-efficacy levels and addiction courses in patients with substance use disorders, was carried out as a randomized controlled experimental study.

NCT ID: NCT05854667 Recruiting - Addiction Clinical Trials

Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic. The main questions the trial aims to answer are: Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine? Participants will be placed randomly into one of four groups: 1. Usual treatment and placebo 2. Usual treatment, placebo and contingency management 3. Usual treatment and high dose stimulant 4. Usual treatment, high dose stimulant and contingency management Participation includes the following: 1. Participants will receive medication or placebo weekly for 15 weeks. 2. Participants will attend the clinic for weekly treatment 3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.

NCT ID: NCT05757453 Completed - Addiction Clinical Trials

Boost Study 31380 (mHealth)

Start date: April 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research is to examine the potential for a new software-based behavioral support approach, for individuals with opioid use disorder, as an addition to usual care.

NCT ID: NCT05700305 Completed - Chronic Disease Clinical Trials

Physical Rehabilitation Intervention With Protein Supplementation for People With Problematic Substance Use and Homelessness

Start date: October 10, 2022
Phase:
Study type: Observational

Background: People who are homeless are more likely to experience poor mental health and addiction as well as suffering from non-communicable diseases. There is evidence of frailty and accelerated physical ageing among people experiencing homelessness. Appropriate physical rehabilitation and nutritional supplementation strategies can stabilize or reverse frailty and general physical decline, but it is not known how this type of intervention would work in practice in this population. Aim: To evaluate the feasibility and preliminary efficacy of a physical rehabilitation drop in intervention with protein supplementation to target physical functioning and frailty in people with problematic substance use who are experiencing homelessness. Methods: The intervention will consist of a 12-week low threshold physical rehabilitation program with protein supplementation. Participants will be service users of the Advance Ballyfermot Project, a day services center for people who are homeless and have active addiction issues. Primary outcomes will be feasibility including numbers recruited, retention of participants and number of repeat visits. Any adverse events will be recorded. Secondary outcomes will be strength and muscular mass, physical performance and lower extremity physical function, pain, frailty and nutritional status.

NCT ID: NCT05609474 Recruiting - Addiction Clinical Trials

Trajectories and Reactions of Users and Relatives Consulting French Youth Addiction Services

TRYAD
Start date: February 15, 2023
Phase:
Study type: Observational [Patient Registry]

In France, the "Consultations Jeunes Consommateurs" (CJC) are the services specialized in the reception of young people for addiction problems. There are more than 500 CJCs throughout France. Depending on the situation, the CJC develops an early intervention strategy aimed either at reducing the risk of developing an addiction or at accelerating entry into appropriate care. The CJCs also meet with family members or professionals who may also independently request help or advice. Set up by the State since 2004, the action of the CJCs has never been formally evaluated. Only descriptive studies, carried out by the French Observatory of Drugs and Drug Addiction (OFDT), have made it possible to better understand the profile of people who consult CJCs. However, no longitudinal study has yet been carried out to understand the factors associated with the overall evolution of users consulting CJCs, nor with the level of satisfaction of users and those around them. Such objectives are complex, due to the diversity of situations encountered in CJCs and the heterogeneity of the CJCs themselves.

NCT ID: NCT05605106 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Addiction and Acute Coronary Syndrome

Start date: December 1, 2022
Phase:
Study type: Observational

the study aims to 1. identify the effect of addiction on TIMI flow in patients presented with acute coronary syndrome. 2. identify the effect of addiction on outcomes of medical treatment of patients presenting with acute coronary syndrome. 3. identify the relation between addiction and LV function. 4. detect the effect of duration of addiction on myocardial infarction lesion and outcomes of pci.

NCT ID: NCT05595759 Recruiting - Addiction Clinical Trials

Violence Against Women in Patients With Alcohol Substance Addiction Training

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study was planned as a randomized controlled trial in order to determine the effect of creative drama training for alcohol-substance dependent male patients on their attitudes towards violence against women.

NCT ID: NCT05577026 Active, not recruiting - Clinical trials for Opioid-Related Disorders

Safe Prescription of Opioids in Primary Care

Start date: February 9, 2023
Phase: N/A
Study type: Interventional

Opioid analgesics are commonly prescribed addictive narcotics intended for the treatment of pain. Inappropriate prescription of opioids in quantities and for conditions which lack clinical evidence contributes to the risk of misuse and addiction. The majority of opioid prescriptions are written by physicians (general practitioners) in primary health care (PHC). PHC is thus an important setting for efforts to encourage the safe and appropriate prescription of opioids. Increasing knowledge of pain treatment recommendations, risks of opioids, and guidelines for the prescription of opioids may decrease inappropriate prescription, and thereby risk of tolerance, dependence, and addiction.

NCT ID: NCT05485181 Completed - Addiction Clinical Trials

Validating Promoted Spiritual Experience

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

This pilot study of 16 patients will demonstrate a specific psychologically focused intervention to affect a spiritual aspect of psychological health and will measure (1) its effects on general distress, depression, anxiety and well-being; (2) healing and psychological impact beyond that accounted by usual personality factors; (3) its effect in correlation to measures of spirituality; (4) with neuroimaging, possible biological changes associated with this intervention. A. Objectives 1. Pilot a psychological intervention that impacts a "spiritual" level. 2. Measure efficacy improving well-being beyond explanation by usual personality factors. 3. Identify biological changes with neuroimaging. B. Hypotheses / Research Question(s) Studies demonstrate a healing effect beyond usual psychological and medical health to include a "spiritual" aspect with added experience of wholeness and well-being. Benefits are beyond just symptom relief but methods to achieve this are not well-defined. This study will provide a specific intervention and measure psychological and neuroimaging effects of the intervention. Hypotheses of Specific Results (see Study Instruments below) 1. DASS-21-shows significant decrease in depression, anxiety and overall stress. 2. PCL-5 - shows decrease 5-10 points (5 points=response, 10 points=clinically meaningful). 3. NIH-HEALS - shows significant increase overall and in all 3 factors. 4. WEMWBS - shows increase of greater than 3 points, considered "meaningful change." 5. Contingencies of Self-Worth Scale-shows significant global increase, positively correlated with increase in Mysticism Scale scores with post-intervention total above standardized mean. 6. A relevant portion of outcome improvement on DASS-21, NIH-HEALS, and ASPIRES will NOT be accountable by personality factors measured by NEO-FFI-3. 7. ASPIRES-shows significant increase in transcendence, no change in religious sentiments. 8. Neuroimaging-shows reduced activity in SPL, TPJ, MPFC, and IPL (see Research Significance).